Want to see VTVT full AI Analyst Report?
VTVT Stock Chart & Stats
$30.73
$0.29(0.94%)
At close: 4:00 PM EDT
$30.73
$0.29(0.94%)
Day’s Range― - ―
52-Week Range$14.55 - $44.00
Previous Close$31.02
Volume63.29K
Average Volume (3M)5.07K
Market Cap
$121.98M
Enterprise Value$380.57
Total Cash (Recent Filing)$86.64M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Nov 05, 2026EPS Estimate
-1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding3,953,928
10 Day Avg. Volume5,801
30 Day Avg. Volume5,072
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)5.23
Price to Sales (P/S)0.00
P/FCF Ratio-13.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$58.20Price Target Upside89.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.55
Revenue Forecast (FY)$37.36M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Repaired Balance SheetZero reported debt and materially improved equity provide durable financial flexibility for a clinical-stage biopharma. This reduces near-term insolvency risk, supports funding trial milestones, and increases optionality for partnering or negotiating licensing deals over the next several quarters.
Growing Non-dilutive Milestone-like RevenueA material pickup in TTM revenue, coupled with near-100% gross margins, suggests the company is generating high-quality, milestone/licensing style revenue. Such revenue is durable relative to R&D success signals and can fund programs or make the firm more attractive to partners without recurring manufacturing costs.
Focused Pipeline Addressing Unmet T1D NeedAdvancing cadisegliatin as a potential first oral adjunctive therapy for hypoglycemia targets a clear structural unmet need in T1D care. If clinical success continues, this could create a differentiated, durable product opportunity driving licensing interest, partnerships, and long-term commercial potential.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow (-$7.6M TTM) means the company is not self-funding development. Over the coming 2–6 months this necessitates external financing or partner funding to sustain trials, limiting strategic choices and increasing execution risk if capital markets tighten.
Ongoing Operating LossesNegative EBIT and net losses reflect that R&D investment currently outpaces revenue generation. Continued unprofitability constrains retained-earnings accumulation and requires external capital to progress programs, elevating financial and execution risk until a sustainable path to profitability is established.
Reliance On Equity Financing (AT‑the‑market Program)Expanding the ATM share program signals structural dependence on equity markets to fund operations. That reliance increases dilution risk for existing shareholders and can limit long-term investor appetite, potentially constraining strategic flexibility and increasing pressure to time financings within the next several quarters.
vTv Therapeutics News
VTVT FAQ
What was vTv Therapeutics’s price range in the past 12 months?
vTv Therapeutics lowest stock price was $14.55 and its highest was $44.00 in the past 12 months.
What is vTv Therapeutics’s market cap?
vTv Therapeutics’s market cap is $121.98M.
When is vTv Therapeutics’s upcoming earnings report date?
vTv Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 82 days.
How were vTv Therapeutics’s earnings last quarter?
vTv Therapeutics released its earnings results on Aug 06, 2026. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.97 by -$0.08.
Is vTv Therapeutics overvalued?
According to Wall Street analysts vTv Therapeutics’s price is currently Undervalued.
Does vTv Therapeutics pay dividends?
vTv Therapeutics does not currently pay dividends.
What is vTv Therapeutics’s EPS estimate?
vTv Therapeutics’s EPS estimate is -1.15.
How many shares outstanding does vTv Therapeutics have?
vTv Therapeutics has 3,953,928 shares outstanding.
What happened to vTv Therapeutics’s price movement after its last earnings report?
vTv Therapeutics reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.97. Following the earnings report the stock price went up 0.64%.
Which hedge fund is a major shareholder of vTv Therapeutics?
Currently, no hedge funds are holding shares in VTVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
vTv Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.20 (89.39% Upside)
$58.20 (89.39% Upside)
Blogger Sentiment
Bullish
VTVT Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
231.19%
Trailing 12-Months
Company Description
vTv Therapeutics
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
VTVT Stock 12 Month Forecast
Average Price Target
$58.20
▲(89.39% Upside)
Technical Analysis
Ownership Overview
11.48% Insiders
9.99% Mutual Funds
19.37% Other Institutional Investors
56.54% Public Companies and
Individual Investors